Non-invasive assessment of local glucose levels and the uptake and metabolism of glucose in tumour in the human brain using Magnetic Resonance at 3T.

Non-invasive assessment of local glucose levels and the uptake and metabolism of glucose in tumour in the human brain using Magnetic Resonance at 3T. - 13C-MRS of human brain tumour

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29778

Enrollment

Registered

2006-11-23

Start date

2006-08-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumour malignant neoplasm in the brain

Interventions

The intervention is the application of an euglycemic clamp.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with a recurrent brain tumor. patients who are willing to lay down in the scanner for 3 hours

Exclusion criteria

Exclusion criteria: MRI contra indication; pacemaker, cerebral clips, metal splinters, neuro stimulator, severe claustrofobia, pregnancy Patienten die zich reeds presenteerden met epilepsie en hiervoor behandeld worden met anti-epileptica

Design outcomes

Primary

Measure	Time frame
During euglycemic condition (blood glucose level of ~5.3 mM) the primary glucose levels and the uptake and metabolic rate of 13C-labeled glucose in the brain are determined. The pilot study is finished when all measurements can successfully be performed. In this case the report of the pilot study will be used to design a larger study to develop the 13C-MRS method further and to verify the results.	—

Measure

Time frame

During euglycemic condition (blood glucose level of ~5.3 mM) the primary glucose levels and the uptake and metabolic rate of 13C-labeled glucose in the brain are determined. The pilot study is finished when all measurements can successfully be performed. In this case the report of the pilot study will be used to design a larger study to develop the 13C-MRS method further and to verify the results.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)